MLYS Stock Summary and Trading Ideas (Mineralys Therapeutics | NASDAQ:MLYS)

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.

As of January 29, 2026, MLYS stock price declined to $32.09 with 492,221 million shares trading.

MLYS has a beta of 0.76, meaning it tends to be less sensitive to market movements. MLYS has a correlation of 0.02 to the broad based SPY ETF.

MLYS has a market cap of $2.54 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that MLYS belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.

MLYS has outperformed the market in the last year with a price return of +209.7% while the SPY ETF gained +16.5%. However, in the short term, MLYS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -20.1% vs +1.3% return in SPY. But in the last 2 weeks, MLYS shares have fared better than the market returning +2.3% compared to SPY +0.3%.

MLYS support price is $31.13 and resistance is $33.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.